OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer: an FDA pooled analysis
Bernardo H. L. Goulart, Sirisha L. Mushti, Somak Chatterjee, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 4, pp. 455-462
Closed Access | Times Cited: 13
Bernardo H. L. Goulart, Sirisha L. Mushti, Somak Chatterjee, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 4, pp. 455-462
Closed Access | Times Cited: 13
Showing 13 citing articles:
Development of a Joint Tumor Size–Overall Survival Modeling and Simulation Framework Supporting Oncology Development Decision‐Making
Herbert Struemper, Chetan Rathi, Morris Muliaditan, et al.
CPT Pharmacometrics & Systems Pharmacology (2025)
Open Access | Times Cited: 1
Herbert Struemper, Chetan Rathi, Morris Muliaditan, et al.
CPT Pharmacometrics & Systems Pharmacology (2025)
Open Access | Times Cited: 1
Proportion of patients in phase 2 oncology trials receiving treatments that are ultimately approved
Charlotte Ouimet, Bertalan Fodor, Joseph C. Del Paggio, et al.
JNCI Journal of the National Cancer Institute (2025)
Closed Access | Times Cited: 1
Charlotte Ouimet, Bertalan Fodor, Joseph C. Del Paggio, et al.
JNCI Journal of the National Cancer Institute (2025)
Closed Access | Times Cited: 1
Frequently asked questions on surrogate endpoints in oncology-opportunities, pitfalls, and the way forward
Abhenil Mittal, Myung Sun Kim, S. Terence Dunn, et al.
EClinicalMedicine (2024), pp. 102824-102824
Open Access | Times Cited: 4
Abhenil Mittal, Myung Sun Kim, S. Terence Dunn, et al.
EClinicalMedicine (2024), pp. 102824-102824
Open Access | Times Cited: 4
Rutecarpine Suppresses Non‐Small Cell Lung Cancer Progression Through Activating the STING Pathway and Elevating CD8 + T Cells
Zebo Jiang, Qiang He, Liping Kang, et al.
Chemical Biology & Drug Design (2025) Vol. 105, Iss. 2
Closed Access
Zebo Jiang, Qiang He, Liping Kang, et al.
Chemical Biology & Drug Design (2025) Vol. 105, Iss. 2
Closed Access
Research Progress on Factors of Immunotherapy Resistance in Non-Small Cell Lung Cancer
峰 赵
Advances in Clinical Medicine (2025) Vol. 15, Iss. 03, pp. 846-852
Closed Access
峰 赵
Advances in Clinical Medicine (2025) Vol. 15, Iss. 03, pp. 846-852
Closed Access
Immunotherapy in mesothelioma – systematic review and meta-analysis of immunotherapy impact on OS and its correlation with PFS and ORR
Marko Skelin, Katarina Matić, Andrea Anić-Matić, et al.
Journal of Chemotherapy (2025), pp. 1-12
Closed Access
Marko Skelin, Katarina Matić, Andrea Anić-Matić, et al.
Journal of Chemotherapy (2025), pp. 1-12
Closed Access
Pragmaticism in Cancer Clinical Trials
K. Nathan Sankar, Mary W. Redman, Konstantin H. Dragnev, et al.
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 3
K. Nathan Sankar, Mary W. Redman, Konstantin H. Dragnev, et al.
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 3
PD-L1 as a predictive factor for non-small-cell lung cancer prognosis
Long Chen, Xian-Ze Zhu, Shijie Zhao, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 6, pp. e233-e233
Closed Access | Times Cited: 2
Long Chen, Xian-Ze Zhu, Shijie Zhao, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 6, pp. e233-e233
Closed Access | Times Cited: 2
The role of PD-L1 in patients with non-small cell lung cancer receiving neoadjuvant immune checkpoint inhibitor plus chemotherapy: a meta-analysis
Dun‐Chang Mo, Jianfeng Huang, Peng Lin, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 2
Dun‐Chang Mo, Jianfeng Huang, Peng Lin, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 2
Identification and validation of GIMAP family genes as immune-related prognostic biomarkers in lung adenocarcinoma
Yanyan Zhang, Shan Liu, Deyi Liu, et al.
Heliyon (2024) Vol. 10, Iss. 12, pp. e33111-e33111
Open Access
Yanyan Zhang, Shan Liu, Deyi Liu, et al.
Heliyon (2024) Vol. 10, Iss. 12, pp. e33111-e33111
Open Access
Plasma proteome-based test (PROphetNSCLC) predicts response to immune checkpoint inhibitors (ICI) independent of tumor programmed death-ligand 1(PD-L1) expression and tumor mutational burden (TMB)
Yehuda Brody, Ben Yellin, Itamar Sela, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Yehuda Brody, Ben Yellin, Itamar Sela, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
A phase 2 single-arm trial of high-dose precision targeted radiotherapy added to immunotherapy for patients with metastatic non-small cell lung cancer
Michael F. Gensheimer, Nikhil V. Kotha, Lucas K. Vitzthum, et al.
International Journal of Radiation Oncology*Biology*Physics (2024) Vol. 121, Iss. 3, pp. 711-719
Closed Access
Michael F. Gensheimer, Nikhil V. Kotha, Lucas K. Vitzthum, et al.
International Journal of Radiation Oncology*Biology*Physics (2024) Vol. 121, Iss. 3, pp. 711-719
Closed Access
Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1%–49%): TOPGAN2023-01
Hisashi Tanaka, Tomonori Makiguchi, Takehiro Tozuka, et al.
European Journal of Cancer (2024) Vol. 213, pp. 115117-115117
Closed Access
Hisashi Tanaka, Tomonori Makiguchi, Takehiro Tozuka, et al.
European Journal of Cancer (2024) Vol. 213, pp. 115117-115117
Closed Access
